Compare Johnson & Johnson (JNJ) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Walmart Stores Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Walmart Stores Inc trades at $111.35 (market cap $877.15B). The key difference: Walmart Stores Inc is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Walmart Stores Inc for 101 Days on average.
| JNJ | WMT | |
|---|---|---|
Market Cap | $618.09B | $877.15B |
Volume | 6,050,983 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $134.20 |
52-Week Low | $186.00 | $100.61 |
Typical Hold Time | 129 Days | 101 Days |
Enterprise Value | $646.37B | $939.38B |
Dividend Yield | 2.09% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Walmart (WMT) trades at $108.11, up 0.82% today, with a neutral technical signal and strong fundamentals. Revenue grew to $681.0B in 2025, with net income rising to $19.4B and a 2.85% margin. The company has beaten EPS estimates for three consecutive quarters, and analyst consensus is a Buy with a $128.84 price target. Recent news highlights expansion in AI, e-commerce, and Medicare Advantage plans, supporting market share gains.
The outlook is positive due to consistent earnings beats, digital growth, and strategic initiatives, but risks include high valuation (P/E 40.06), rising costs, and economic sensitivity. Upside potential exists toward the consensus target, though near-term volatility may persist amid inflation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
